CAR-T Meeting 2024 | Optimizing CAR-T therapy: regulating CAR T-cells in vivo
Charlotte Zajc, PhD, University of Natural Resources and Life Sciences, Vienna, Austria, explores optimizing CAR T-cell therapies to enhance efficacy while minimizing side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Dr Zajc emphasizes the importance of controlling CAR T-cells within the patient, suggesting methods such as employing ON- and OFF-switches with small molecule drugs or resting CAR T-cells through dasatinib administration. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Patent related to ON-switches. Funding received by Miltenyi Biotec.
